Stockscreener 앱 받기
1.44%
시간 외 거래:
전일 마감가:
$24.23
열려 있는:
$24.2899
하루 거래량:
36.35M
Relative Volume:
0.86
시가총액:
$139.75B
수익:
$63.83B
순이익/손실:
$10.75B
주가수익비율:
13.07
EPS:
1.88
순현금흐름:
$12.44B
1주 성능:
+4.64%
1개월 성능:
-4.06%
6개월 성능:
-4.51%
1년 성능:
-14.53%
1일 변동 폭
$24.16
$24.61
1주일 범위
$23.40
$24.89
52주 변동 폭
$20.91
$30.43
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
PFE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.58 | 136.06B | 63.83B | 10.75B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
625.65 | 670.04B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
173.33 | 410.84B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
198.05 | 346.78B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
116.84 | 219.72B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
80.69 | 198.42B | 63.62B | 16.41B | 14.72B | 6.49 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
2 Beaten-Down Stocks to Buy and Hold - The Motley Fool
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
FDA Accepts Pfizer (PFE) Vepdegestrant NDA for Breast Cancer, Fast Track Designation Awarded - simplywall.st
GlaxoSmithKline Will Get $500M In CureVac-Pfizer Patent Deal - Law360
Pfizer and Arvinas' breast cancer therapy to be reviewed by FDA - Seeking Alpha
Arvinas and Pfizer Announce FDA Acceptance of NDA for Vepdegestrant Following Positive Phase 3 VERITAC-2 Trial Results in Advanced Breast Cancer - Quiver Quantitative
Pfizer’s Clinical Study on Drug Interactions in Obesity Treatment: Key Update - The Globe and Mail
CureVac and GSK to receive money and royalties from BioNTech/Pfizer as part of mRNA patent settlement - Endpoints News
Rx Rundown: Pfizer, SERB Pharmaceuticals, Novo Nordisk and more - Medical Marketing and Media
CureVac Enters Agreements to Resolve mRNA Patent Litigation with Pfizer/BioNTech - Contract Pharma
CureVac announces resolution of patent litigation with Pfizer/BioNTech - Medical Dialogues
GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - MSN
CureVac and GSK settle mRNA patent dispute with Pfizer and BioNTech - Reuters
GSK and CureVac settle mRNA patent spat with Pfizer/BioNTech - pharmaphorum
Pfizer and AbbVie Collaborate on Promising Pediatric Antibiotic Study - TipRanks
GSK Set for $500 Million Payment From mRNA Lawsuit Settlement - Bloomberg.com
Pfizer (PFE) Releases Financial Results for Q2 2025 - Insider Monkey
Pfizer’s MEVPRO-1 Study: A New Frontier in Prostate Cancer Treatment - TipRanks
Pfizer’s New Study on PF-07799544: A Potential Game-Changer in Cancer Treatment - TipRanks
CureVac settles mRNA patent dispute litigation with Pfizer and BioNTech - The Mighty 790 KFGO
Burn Pain Market: Epidemiology, Therapies, Companies, DelveInsight | Johnson & Johnson, Mankind Pharma, Perrigo Company PLC, Pfizer Inc., Smith & Nephew PLC, Sun Pharmaceutical Industries Ltd, Trio Li - Barchart.com
Is Pfizer A Buy After Blowing Away Second-Quarter Views? - Investor's Business Daily
Pfizer’s New Breast Cancer Treatment Study: A Potential Game-Changer? - TipRanks
PFE’s Recent Struggles: A Market Perspective - StocksToTrade
Pfizer’s New Prostate Cancer Study: A Potential Game-Changer? - TipRanks
Pfizer’s Promising Phase 1 Study on PF-07799933 for Advanced Solid Tumors - TipRanks
Pfizer’s ATGAM Study: A Closer Look at Safety in Aplastic Anemia Treatment - TipRanks
Pfizer’s Rimegepant Study: Assessing Safety in Pregnancy - TipRanks
Pfizer’s Inclacumab Study: Long-term Safety Insights for Sickle Cell Disease - TipRanks
Pfizer’s MAGNETISMM-6 Study: A New Horizon in Multiple Myeloma Treatment - TipRanks
Pfizer’s Latest Study on Enfortumab Vedotin: A Boost for Urothelial Cancer Treatment - TipRanks
Pfizer’s Phase 3 RSV Vaccine Study: A Potential Game-Changer for Maternal Health - TipRanks
Pfizer’s Promising Migraine Study: A Potential Game-Changer for Adolescents - TipRanks
Pfizer’s Somatrogon Study in India: A Key Update for Investors - TipRanks
Pfizer and BioNTech’s New Shingles Vaccine Study: A Potential Game-Changer? - TipRanks
Pfizer’s New Prostate Cancer Study: A Potential Game-Changer - TipRanks
Pfizer’s ABRYSVO Vaccine Study: A Potential Game-Changer for Infant RSV Protection - TipRanks
Pfizer’s Korean Surveillance Study: Ensuring Comirnaty’s Safety Post-Market - TipRanks
Arvinas, Pfizer reworking partnership on ‘Protac’ cancer drug - BioPharma Dive
Pfizer's Upcoming Earnings and Strategic Innovation in Biopharma: A Deep Dive into Value Potential - AInvest
United States Pharmaceutical Market Forecast and Company - GlobeNewswire
United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda - Yahoo Finance
Pfizer's Turnaround Has Truly Started (Earnings Update) - Seeking Alpha
Pfizer Romania recognized as a Best Place to Work for 2025 - TradingView
Jim Cramer Warns that Pfizer “Shareholder Base is Getting Very Restive” - Insider Monkey
Pfizer's Strategic Position in the Evolving Health Sector: Navigating Innovation and Regulatory Crosscurrents - AInvest
Pfizer Q2 2025 Earnings: Strong Growth Amid Challenges - The Globe and Mail
Pfizer's Innovation-Driven Turnaround and Its Implications for the Health Sector - AInvest
Pfizer Q2: Dividends Speak Louder Than EPS (NYSE:PFE) - Seeking Alpha
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
8.28%
0.63%
자본화:
|
볼륨(24시간):